Spermosens AB announces strategic collaboration with Scalania AG to accelerate development and market readiness
Regulatory
Spermosens AB (publ) (“Spermosens” or the “Company”) announces a strategic collaboration with Scalania AG (“Scalania”), part of the UNITY Innovation Alliance, to accelerate the development and market readiness of its unique JUNO-Checked technology. Following the previous announcement on March 4th, 2025, the Company has now entered into a strategic collaboration agreement with Scalania, effective from April 2025.
Spermosens publishes peer-reviewed article on JUNO-Checked technology
Regulatory
Spermosens AB (publ) (“Spermosens” or the “Company”) is pleased to announce that a peer-reviewed article, “JUNO-Checked – A Live Cell Electrochemical Biosensor for Sperm Function Diagnostics,” has been published in the prestigious journal Sensors & Diagnostics by the Royal Society of Chemistry. This gold open-access journal is renowned for showcasing cutting-edge research on sensing technologies and diagnostic systems, with a particular focus on novel materials, innovative detection methods and advancements that enable in situ or real-world testing.
Spermosens presents plan to achieve positive cash flow following recent strategic investment
Regulatory
Spermosens AB (publ) (“Spermosens” or the “Company”) presents the plan to achieve positive cash flow following a recent investment by a consortium of investors from Germany, Scandinavia and the United States. The plan includes completion of the ongoing clinical study and advancing the JUNO-Checked technology and system to ensure commercial viability. Through this approach, Spermosens aims to establish licensing agreements with leading players in the assisted reproductive technology (ART) market in the second half of 2026, positioning the company to achieve positive cash flow.
Spermosens AB (publ) (“Spermosens” or the “Company”) today announces the outcome of the TO3 series of warrants, issued in connection with the rights issue announced on 20 February 2024.
Spermosens secures SEK 10.8 million strategic investment through directed issue, fulfilling capital need until cash positive
Regulatory
Spermosens AB (publ) (“Spermosens” or the “Company”) has secured an investment of SEK 10.8 million through a directed issue from a consortium of American and European strategic investors. The investment, which does not include issuance of any warrants, provides funding until H2 2026, when the Company expects to reach cash flow positivity, primarily through income from license agreements with established partners in the global Assisted Reproductive Technology (ART) market.
Spermosens announces last day of trading for warrants of series TO3
Regulatory
Spermosens AB (“Spermosens” or “the Company”) announces that the last day of trading for the warrants of series TO3 on Spotlight Stock Market is 27 February 2025.
Spermosens AB announces shareholding changes following latest directed issue
Regulatory
Spermosens AB (publ) announces changes in its shareholding structure following the latest directed issue. An update of the shareholder structure was made prior to the extraordinary general meeting held on 17 February 2025.
Kommuniké från extra bolagsstämma i Spermosens AB (publ) den 17 februari 2025
Regulatory
Spermosens AB (publ) höll den 17 februari 2025 extra bolagsstämma varvid i huvudsak följande beslut fattades. Beslut om ändring av bolagsordningen Den extra bolagsstämman beslutade, i enlighet med styrelsens förslag, att bemyndiga styrelsen att ändra bolagets bolagsordning genom att anta nya gränser för aktiekapitalet respektive antalet aktier i syfte att möjliggöra emission av aktier och teckningsoptioner. Styrelsen är därmed bemyndigad att ändra bolagets bolagsordning till det av Alternativ A–B som behövs för att möjliggöra emissionerna.
Announcement from the Extraordinary General Meeting of Spermosens AB (publ) on 17 February 2025
Regulatory
Spermosens AB (publ) held an Extraordinary General Meeting on 17 February 2025, during which the following key resolutions were adopted. Resolution to Amend the Articles of Association The Extraordinary General Meeting resolved, in accordance with the Board’s proposal, to authorize the Board to amend the company’s Articles of Association by adopting new limits for share capital and the number of shares to enable the issuance of shares and warrants. The Board is thus authorized to amend the Articles of Association to either of the following alternatives as required to facilitate the issuances:
Spermosens adjusts publication date for Year-end report 2024
Regulatory
Spermosens AB (publ) announces that the company’s Year-end report for 2024, originally scheduled for publication on February 12, 2025, has been postponed to February 13, 2025. The adjustment has been made to align with the calendar availability of the company’s Board of Directors.
Aktieägarna i Spermosens AB (publ), org.nr 559179-0380 (”Bolaget”), kallas till extra bolagsstämma den 17 februari 2025 kl. 15.00 i Bolagets lokaler på Medicon Village Scheeletorget 1, 223 81 i Lund.
Nov 30, 2021 For those of you who missed the presentation at Stora Aktiedagen, Aktiesparararna, or if you want to watch it again, you find the recorded broadcast here.
Sep 13, 2021 Spermosens CEO John Lempert is interviewed by Mikael Bak at Dansk Aktionærforening in a talk about how the company has developed since the IPO in May.
Aug 19, 2021 Spermosens CEO John Lempert is interviewed in Aktier – Live Sessions, the biggest Facebook group in the Nordics covering the stock market. This was recorded on Aug 19th, the day we published our interim report Q2 2021. The topics are connected to the progress made since the IPO.
We may request cookies to be set on your device. We use cookies to let us know how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
Other external services
We use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
Privacy Policy
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
